The US Food and Drug Administration (FDA) has concluded that the existing regulatory framework for some foods and supplements are not appropriate for cannabidiol.
On 26 January, the organisation passed a review that stated a new regulatory pathway for CBD is needed that balances individuals’ desire for access to CBD products with the regulatory oversight needed to manage risks.
In a statement, Janet Woodcock, Principal Deputy Commissioner at Office of the Commissioner, wrote: “The use of CBD raises various safety concerns, especially with long-term use. Studies have shown the potential for harm to the liver, interactions with certain medications and possible harm to the male reproductive system. CBD exposure is also concerning when it comes to certain vulnerable populations such as children and those who are pregnant.”
We have not found adequate evidence to determine how much CBD can be consumed, and for how long, before causing harm
On behalf of the FDA, Woodcock suggested some risk management tools could include clear labels, prevention of contaminants, CBD content limits, and measures, such as minimum purchase age, to mitigate the risk of ingestion by children.
Woodcock continued: “Given the available evidence, it is not apparent how CBD products could meet safety standards for dietary supplements or food additives. For example, we have not found adequate evidence to determine how much CBD can be consumed, and for how long, before causing harm. Therefore, we do not intend to pursue rulemaking allowing the use of CBD in dietary supplements or conventional foods.”
CBD also poses risks to animals, and people could be unknowingly exposed to CBD through meat, milk and eggs from animals fed CBD.